title: Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo.
abstract: Hormone refractory metastatic prostate cancer is a deadly disease that currently lacks curative treatments. Conditionally replicating adenoviruses (CRAds) are promising new agents against cancer due to their innate capability to cause oncolysis of tumor cells. Their antitumor effect is determined in part by their capacity for infecting cancer cells. However, the respective primary receptor, the coxsackie-adenovirus receptor (CAR), is variably expressed in many cancer types. We created Ad5/3Delta24hCG, a novel CRAd retargeted to the adenovirus serotype 3 receptor, which has been reported to be highly expressed in tumors. Furthermore, we added a transgene for the beta-chain of human chorionic gonadotropin (hCGbeta), whose expression was tightly coupled to virus replication. Ad5/3Delta24hCG was found effective in killing prostate cancer cells, and oncolysis was seen in concordance with hCGbeta production. In a s.c. in vivo model of hormone refractory prostate cancer, Ad5/3Delta24hCG treatment resulted in statistically significant tumor growth inhibition. Moreover, i.v. injection of Ad5/3Delta24hCG prolonged the survival of mice with hormone refractory prostate cancer metastatic to the lung. Detection of hCGbeta in serum samples confirmed viral replication in vivo. Infection of human clinical samples of cancerous and normal prostatic tissue resulted in effective hCGbeta production in cancer tissue, whereas it remained low in nonmalignant tissue, suggesting cancer-specific replication. These results suggest that Ad5/3Delta24hCG is a potent virus for the treatment of hormone refractory prostate cancer in vitro and in vivo. These preclinical data set the stage for translation into clinical studies.
authors.affiliation: Molecular Cancer Biology Program, Department of Oncology, University of Helsinki, P.O. Box 63, (Haartmaninkatu 8), Helsinki 00014, Finland.
authors.forename: Maria
authors.initials: M
authors.lastname: Rajecki
authors.forename: Anna
authors.initials: A
authors.lastname: Kanerva
authors.forename: Ulf-Håkan
authors.initials: UH
authors.lastname: Stenman
authors.forename: Mikko
authors.initials: M
authors.lastname: Tenhunen
authors.forename: Lotta
authors.initials: L
authors.lastname: Kangasniemi
authors.forename: Merja
authors.initials: M
authors.lastname: Särkioja
authors.forename: Martti Y
authors.initials: MY
authors.lastname: Ala-Opas
authors.forename: Henrik
authors.initials: H
authors.lastname: Alfthan
authors.forename: Anna
authors.initials: A
authors.lastname: Sankila
authors.forename: Erkki
authors.initials: E
authors.lastname: Rintala
authors.forename: Renee A
authors.initials: RA
authors.lastname: Desmond
authors.forename: Tanja
authors.initials: T
authors.lastname: Hakkarainen
authors.forename: Akseli
authors.initials: A
authors.lastname: Hemminki
mesh_terms: D000256:Adenoviridae / Q000502:physiology*; D000818:Animals; D002470:Cell Survival; D002478:Cells, Cultured; D006063:Chorionic Gonadotropin / Q000235:genetics / Q000494:pharmacology*; D062727:Coxsackie and Adenovirus Receptor-Like Membrane Protein; D004279:DNA, Viral / Q000235:genetics; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D007668:Kidney / Q000378:metabolism / Q000821:virology; D008175:Lung Neoplasms / Q000556:secondary / Q000628:therapy* / Q000821:virology; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009842:Oligopeptides / Q000378:metabolism; D050130:Oncolytic Virotherapy; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000628:therapy* / Q000821:virology; D011991:Receptors, Virus / Q000378:metabolism; D014407:Tumor Cells, Cultured; D014779:Virus Replication; D023041:Xenograft Model Antitumor Assays
chemical_list: C568771:CLMP protein, human; C568772:CLMP protein, mouse; D006063:Chorionic Gonadotropin; D062727:Coxsackie and Adenovirus Receptor-Like Membrane Protein; D004279:DNA, Viral; D009842:Oligopeptides; D011991:Receptors, Virus; C047981:arginyl-glycyl-aspartic acid